Acurx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acurx Pharmaceuticals generated cash of -$9,800,885, which is less than the previous year. Cash used in financing activities reached the amount of $8,163,322 last year. Net change in cash is therefore -$1,637,563.
Cash Flow
| 2019 | -3.98M | 0 | 4.45M |
|---|---|---|---|
| 2020 | -3.35M | 0 | 4.04M |
| 2021 | -5.01M | 0 | 14.79M |
| 2022 | -7.54M | 0 | 3.69M |
| 2023 | -9.80M | 0 | 8.16M |
ACXP Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 9.11M | 12.95M | 3.17M | 2.48M | 2.01M |
Operating activities | |||||
Net income | -14.57M | -12.09M | -12.74M | -4.60M | -5.93M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 3.76M | 3.30M | 6.74M | 1.26M | 900.43K |
| Deferred income tax benefit | 3.76M | 3.30M | 6.74M | 1.26M | 900.43K |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 1.21M | 387.97M | 0 | 0 |
Cash generated by operating activities | -9.80M | -7.54M | -5.01M | -3.35M | -3.98M |
Investing activities | |||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 5 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 |
Financing activities | |||||
Common Stock Issued | 5.94M | 3.69M | 14.79M | 3.97M | 4.45M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -66.50K | 0 |
Cash used in financing activities | 8.16M | 3.69M | 14.79M | 4.04M | 4.45M |
Net Change In Cash | -1.63M | -3.84M | 9.78M | 692.08K | 470.16K |
Cash at end of period | 7.47M | 9.11M | 12.95M | 3.17M | 2.48M |
| Data source | Data source | Data source |